Phoenix Biotech Acquisition Corp. (PBAXU): Price and Financial Metrics


Phoenix Biotech Acquisition Corp. (PBAXU): $10.10

0.03 (+0.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PBAXU Stock Price Chart Interactive Chart >

Price chart for PBAXU

PBAXU Price/Volume Stats

Current price $10.10 52-week high $11.21
Prev. close $10.07 52-week low $9.94
Day low $10.08 Volume 20,300
Day high $10.60 Avg. volume 7,748
50-day MA $10.09 Dividend yield N/A
200-day MA $0.00 Market Cap N/A

Phoenix Biotech Acquisition Corp. (PBAXU) Company Bio


Phoenix Biotech Acquisition Corp. intends to acquire assets and businesses through a merger, share exchange, share purchase, reorganization, or similar business combination. It focuses on pursuing opportunities in the life sciences sector. The company was incorporated in 2021 and is based in Oakland, California.


PBAXU Latest News Stream


Event/Time News Detail
Loading, please wait...

PBAXU Latest Social Stream


Loading social stream, please wait...

View Full PBAXU Social Stream

Latest PBAXU News From Around the Web

Below are the latest news stories about Phoenix Biotech Acquisition Corp that investors may wish to consider to help them evaluate PBAXU as an investment opportunity.

Phoenix Biotech Acquisition Corp. Class A Common Shares and Warrants to Commence Trading Separately on November 26, 2021

Oakland, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU) (the “Company”), a blank-check company formed for the purpose of acquiring or merging with one or more businesses, today announced that the holders of the Company’s units may elect to separately trade the Class A common shares and warrants underlying the units commencing on November 26, 2021. Those units not separated will continue to trade on the NASDAQ Capital Market under the symbol “PBAXU” and the

Yahoo | November 22, 2021

89bio Announces Appointment of Kathy LaPorte to its Board of Directors

SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry lea

Yahoo | November 3, 2021

Phoenix Biotech Acquisition Corp. Announces Completion of $175,000,000 Initial Public Offering, Including Exercise of Over-Allotment Option

Oakland, CA, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU) (the “Company”), a blank-check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, today announced the completion of its initial public offering of 17,500,000 units at a price of $10.00 per unit, which includes 2,000,000 units issued pursuant to the exercise of the underwrit

Yahoo | October 8, 2021

Read More 'PBAXU' Stories Here

PBAXU Price Returns

1-mo 0.20%
3-mo N/A
6-mo 0.60%
1-year N/A
3-year N/A
5-year N/A
YTD 0.10%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5087 seconds.